Abbott’s SPIRITs Are Raised By Positive Drug-Eluting Stent Data At ACC
This article was originally published in The Gray Sheet
Executive Summary
Abbott's SPIRIT III trial for its Xience V everolimus-eluting stent bodes well for the device's market potential and points to a new direction for stent manufacturers' premarket relationship with FDA
You may also be interested in...
EuroPCR 2007 Results Join Growing Mix Of Stent Safety Data
Drug-eluting stent makers continue to battle it out with the release of the latest safety data at the May 22-25 EuroPCR meeting in Barcelona, Spain
EuroPCR 2007 Results Join Growing Mix Of Stent Safety Data
Drug-eluting stent makers continue to battle it out with the release of the latest safety data at the May 22-25 EuroPCR meeting in Barcelona, Spain
Failure Of J&J/Conor’s CoStar Stent Trial Sets Program Back Up To Four Years
Johnson & Johnson's Conor Medsystems unit will discontinue development of its CoStar paclitaxel-eluting coronary stent and terminate sales of the device overseas following the failure of the firm's CoStar II U.S. pivotal study